DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

BACKGROUND: Because the general population is largely naive to H5N1 influenza, antibodies generated to H5 allow analysis of novel influenza vaccines independent of background immunity from previous infection. We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Infect Dis
Main Authors: Ledgerwood, Julie E, Wei, Chih-Jen, Hu, Zonghui, Gordon, Ingelise J, Enama, Mary E, Hendel, Cynthia S, McTamney, Patrick M, Pearce, Melissa B, Yassine, Hadi M, Boyington, Jeffrey C, Bailer, Robert, Tumpey, Terrence M, Koup, Richard A, Mascola, John R, Nabel, Gary J, Graham, Barney S
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Ltd. 2011
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185472/
https://ncbi.nlm.nih.gov/pubmed/21975270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(11)70240-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados